heartburn cancer uk
heartburn cancer uk Company Information
Company Number
07227937
Next Accounts
Jan 2026
Shareholders
-
Group Structure
View All
Industry
Other human health activities
Registered Address
grove house lutyens close, chineham court, basingstoke, hampshire, RG24 8AG
Website
www.heartburncanceruk.orgheartburn cancer uk Estimated Valuation
Pomanda estimates the enterprise value of HEARTBURN CANCER UK at £137.5k based on a Turnover of £275.7k and 0.5x industry multiple (adjusted for size and gross margin).
heartburn cancer uk Estimated Valuation
Pomanda estimates the enterprise value of HEARTBURN CANCER UK at £206.3k based on an EBITDA of £53.7k and a 3.84x industry multiple (adjusted for size and gross margin).
heartburn cancer uk Estimated Valuation
Pomanda estimates the enterprise value of HEARTBURN CANCER UK at £605.9k based on Net Assets of £257.9k and 2.35x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Heartburn Cancer Uk Overview
Heartburn Cancer Uk is a live company located in basingstoke, RG24 8AG with a Companies House number of 07227937. It operates in the other human health activities sector, SIC Code 86900. Founded in April 2010, it's largest shareholder is unknown. Heartburn Cancer Uk is a established, micro sized company, Pomanda has estimated its turnover at £275.7k with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Heartburn Cancer Uk Health Check
Pomanda's financial health check has awarded Heartburn Cancer Uk a 5 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 2 areas for improvement. Company Health Check FAQs
5 Strong
2 Regular
2 Weak
Size
annual sales of £275.7k, make it smaller than the average company (£641.2k)
£275.7k - Heartburn Cancer Uk
£641.2k - Industry AVG
Growth
3 year (CAGR) sales growth of 30%, show it is growing at a faster rate (8%)
30% - Heartburn Cancer Uk
8% - Industry AVG
Production
with a gross margin of 39.2%, this company has a comparable cost of product (39.2%)
39.2% - Heartburn Cancer Uk
39.2% - Industry AVG
Profitability
an operating margin of 15.9% make it more profitable than the average company (5.5%)
15.9% - Heartburn Cancer Uk
5.5% - Industry AVG
Employees
with 3 employees, this is below the industry average (16)
3 - Heartburn Cancer Uk
16 - Industry AVG
Pay Structure
on an average salary of £28.9k, the company has an equivalent pay structure (£27.2k)
£28.9k - Heartburn Cancer Uk
£27.2k - Industry AVG
Efficiency
resulting in sales per employee of £91.9k, this is more efficient (£49.1k)
£91.9k - Heartburn Cancer Uk
£49.1k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Heartburn Cancer Uk
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Heartburn Cancer Uk
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Heartburn Cancer Uk
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 3016 weeks, this is more cash available to meet short term requirements (106 weeks)
3016 weeks - Heartburn Cancer Uk
106 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 1.4%, this is a lower level of debt than the average (25.8%)
1.4% - Heartburn Cancer Uk
25.8% - Industry AVG
HEARTBURN CANCER UK financials
Heartburn Cancer Uk's latest turnover from April 2024 is £275.7 thousand and the company has net assets of £257.9 thousand. According to their latest financial statements, Heartburn Cancer Uk has 3 employees and maintains cash reserves of £206.5 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 | Apr 2016 | Apr 2015 | Apr 2014 | Apr 2013 | Apr 2012 | Apr 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 275,737 | 174,913 | 167,898 | 124,297 | 94,466 | 84,542 | 29,700 | 30,484 | 37,212 | 54,926 | ||||
| Other Income Or Grants | ||||||||||||||
| Cost Of Sales | ||||||||||||||
| Gross Profit | ||||||||||||||
| Admin Expenses | ||||||||||||||
| Operating Profit | ||||||||||||||
| Interest Payable | ||||||||||||||
| Interest Receivable | ||||||||||||||
| Pre-Tax Profit | 40,603 | 59,093 | 31,806 | 20,136 | 9,174 | 37,300 | 1,300 | 23,439 | -9,410 | 25,784 | ||||
| Tax | ||||||||||||||
| Profit After Tax | 40,603 | 59,093 | 31,806 | 20,136 | 9,174 | 37,300 | 1,300 | 23,439 | -9,410 | 25,784 | ||||
| Dividends Paid | ||||||||||||||
| Retained Profit | 40,603 | 59,093 | 31,806 | 20,136 | 9,174 | 37,300 | 1,300 | 23,439 | -9,410 | 25,784 | ||||
| Employee Costs | 86,802 | 64,302 | 59,175 | 53,212 | 32,653 | 12,970 | ||||||||
| Number Of Employees | 3 | 3 | 3 | 2 | 2 | 1 | ||||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 | Apr 2016 | Apr 2015 | Apr 2014 | Apr 2013 | Apr 2012 | Apr 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 52,101 | 16,234 | 21,646 | 27,058 | ||||||||||
| Intangible Assets | ||||||||||||||
| Investments & Other | ||||||||||||||
| Debtors (Due After 1 year) | ||||||||||||||
| Total Fixed Assets | 52,101 | 16,234 | 21,646 | 27,058 | ||||||||||
| Stock & work in progress | ||||||||||||||
| Trade Debtors | 110 | |||||||||||||
| Group Debtors | ||||||||||||||
| Misc Debtors | 2,896 | 12,168 | 36,666 | 7,203 | 9,999 | 1,716 | 25 | |||||||
| Cash | 206,503 | 191,435 | 117,777 | 92,735 | 100,819 | 102,272 | 60,008 | 58,528 | 35,089 | 44,499 | 40,812 | 42,951 | 37,850 | 26,449 |
| misc current assets | ||||||||||||||
| total current assets | 209,399 | 203,603 | 154,443 | 99,938 | 110,818 | 103,988 | 60,008 | 58,528 | 35,089 | 44,499 | 40,812 | 42,951 | 37,850 | 26,584 |
| total assets | 261,500 | 219,837 | 176,089 | 126,996 | 110,818 | 103,988 | 60,008 | 58,528 | 35,089 | 44,499 | 40,812 | 42,951 | 37,850 | 26,584 |
| Bank overdraft | ||||||||||||||
| Bank loan | ||||||||||||||
| Trade Creditors | 324 | 57 | 2,485 | 20 | 200 | |||||||||
| Group/Directors Accounts | ||||||||||||||
| other short term finances | ||||||||||||||
| hp & lease commitments | ||||||||||||||
| other current liabilities | 3,560 | 2,500 | 17,845 | 234 | 4,459 | 4,375 | 180 | 600 | ||||||
| total current liabilities | 3,560 | 2,500 | 17,845 | 558 | 4,516 | 6,860 | 180 | 20 | 800 | |||||
| loans | ||||||||||||||
| hp & lease commitments | ||||||||||||||
| Accruals and Deferred Income | ||||||||||||||
| other liabilities | ||||||||||||||
| provisions | ||||||||||||||
| total long term liabilities | ||||||||||||||
| total liabilities | 3,560 | 2,500 | 17,845 | 558 | 4,516 | 6,860 | 180 | 20 | 800 | |||||
| net assets | 257,940 | 217,337 | 158,244 | 126,438 | 106,302 | 97,128 | 59,828 | 58,528 | 35,089 | 44,499 | 40,812 | 42,951 | 37,830 | 25,784 |
| total shareholders funds | 257,940 | 217,337 | 158,244 | 126,438 | 106,302 | 97,128 | 59,828 | 58,528 | 35,089 | 44,499 | 40,812 | 42,951 | 37,830 | 25,784 |
| Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 | Apr 2016 | Apr 2015 | Apr 2014 | Apr 2013 | Apr 2012 | Apr 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | ||||||||||||||
| Depreciation | 10,000 | 5,412 | 5,412 | |||||||||||
| Amortisation | ||||||||||||||
| Tax | ||||||||||||||
| Stock | ||||||||||||||
| Debtors | -9,272 | -24,498 | 29,463 | -2,796 | 8,283 | 1,716 | -135 | 135 | ||||||
| Creditors | -324 | 267 | -2,428 | 2,485 | -20 | -180 | 200 | |||||||
| Accruals and Deferred Income | 1,060 | -15,345 | 17,611 | -4,225 | 84 | 4,195 | 180 | -600 | 600 | |||||
| Deferred Taxes & Provisions | ||||||||||||||
| Cash flow from operations | ||||||||||||||
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | ||||||||||||||
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | ||||||||||||||
| Group/Directors Accounts | ||||||||||||||
| Other Short Term Loans | ||||||||||||||
| Long term loans | ||||||||||||||
| Hire Purchase and Lease Commitments | ||||||||||||||
| other long term liabilities | ||||||||||||||
| share issue | ||||||||||||||
| interest | ||||||||||||||
| cash flow from financing | ||||||||||||||
| cash and cash equivalents | ||||||||||||||
| cash | 15,068 | 73,658 | 25,042 | -8,084 | -1,453 | 42,264 | 1,480 | 23,439 | -9,410 | 3,687 | -2,139 | 5,101 | 11,401 | 26,449 |
| overdraft | ||||||||||||||
| change in cash | 15,068 | 73,658 | 25,042 | -8,084 | -1,453 | 42,264 | 1,480 | 23,439 | -9,410 | 3,687 | -2,139 | 5,101 | 11,401 | 26,449 |
heartburn cancer uk Credit Report and Business Information
Heartburn Cancer Uk Competitor Analysis
Perform a competitor analysis for heartburn cancer uk by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other micro companies, companies in RG24 area or any other competitors across 12 key performance metrics.
heartburn cancer uk Ownership
HEARTBURN CANCER UK group structure
Heartburn Cancer Uk has no subsidiary companies.
Ultimate parent company
HEARTBURN CANCER UK
07227937
heartburn cancer uk directors
Heartburn Cancer Uk currently has 8 directors. The longest serving directors include Ms Mimi McCord (May 2010) and Professor Rebecca Fitzgerald (May 2010).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Ms Mimi McCord | 66 years | May 2010 | - | Director | |
| Professor Rebecca Fitzgerald | England | 56 years | May 2010 | - | Director |
| Mrs Beryl Huntingdon | 80 years | Aug 2013 | - | Director | |
| Dr Oliver Stovin | 66 years | Apr 2022 | - | Director | |
| Mr William Mathers | England | 74 years | Jul 2022 | - | Director |
| Mr Michael Farrier | 66 years | Nov 2023 | - | Director | |
| Mrs Jo Stevenson Timini | 55 years | Dec 2023 | - | Director | |
| Professor Sheraz Markar | 41 years | Jul 2024 | - | Director |
P&L
April 2024turnover
275.7k
+58%
operating profit
43.7k
0%
gross margin
39.3%
+2.59%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
April 2024net assets
257.9k
+0.19%
total assets
261.5k
+0.19%
cash
206.5k
+0.08%
net assets
Total assets minus all liabilities
heartburn cancer uk company details
company number
07227937
Type
Private Limited by guarantee without Share Capital Exempt from using Limited
industry
86900 - Other human health activities
incorporation date
April 2010
age
15
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
April 2024
previous names
heartburn cancer awareness and support (September 2014)
accountant
N R WHITEMORE
auditor
-
address
grove house lutyens close, chineham court, basingstoke, hampshire, RG24 8AG
Bank
C A F BANK
Legal Advisor
-
heartburn cancer uk Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to heartburn cancer uk.
heartburn cancer uk Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for HEARTBURN CANCER UK. This can take several minutes, an email will notify you when this has completed.
heartburn cancer uk Companies House Filings - See Documents
| date | description | view/download |
|---|
